Abstract: The present invention relates to a recombinant vaccine against Lawsonia intracellularis, based on a recombinant synthetic chimeric variant of membrane proteins and invasins of said bacteria. In addition, the invention discloses synthetic nucleotide sequences encoding said protein variants, recombinant proteins as such, an expression cassette of said synthetic protein antigens, a transformed cell, and a method for producing said antigens, demonstrating the antigenicity and protective potential thereof against the pathogen Lawsonia intracellularis.

Abstract: The present invention relates to the technical field of Biotechnology and the obtaining of molecules by recombinant DNA technology, in particular it refers to a synthetic polynucleotide sequence encoding a single-chain recombinant bovine follicle-stimulating hormone, comprising a first polynucleotide enconding the beta subunit of the Bos taurus follicle-stimulating hormone having sequence SEQ ID No. 1, or a variant thereof with at least 85% sequence identity therewith; a second polynucleotide encoding the alpha subunit of the Bos taurus follicle-stimulating hormone having sequence SEQ ID No. 2 or a variant thereof with at least 85% sequence identity therewith; and a third polynucleotide linking said first and second polynucleotides, which encodes a spacer sequence derived from human keratin 10 having sequence SEQ ID No. 3 or a variant.

Abstract: The present invention relates to a recombinant vaccine against Lawsonia intracellularis, based on a recombinant synthetic chimeric variant of membrane proteins and invasins of said bacteria. In addition, the invention discloses synthetic nucleotide sequences encoding said protein variants, recombinant proteins as such, an expression cassette of said synthetic protein antigens, a transformed cell, and a method for producing said antigens, demonstrating the antigenicity and protective potential thereof against the pathogen Lawsonia intracellularis.

Abstract: The current invention describes chimeric vaccine antigens against the virus that causes the Classic Swine Fever (CSFV). Such vaccine antigens are based on viral subunits coupled to proteins able to stimulate cellular and humoral immune system. Chimeric antigens can be produced in expression systems that guarantee a correct tertiary structure folding of the chimeric molecules, which constitute the essence of the current invention. The vaccine formulations containing such chimeric antigens induce an early and potent immune response on vaccinated pigs and confer full protection against CSFV. Moreover, the resultant vaccine formulations prevent the viral transmission from sows to their offspring. The chimeric antigens, as well as the resultant vaccine formulations, can be applied in animal health as vaccines for preventive use in swine.

Abstract: The present invention describes chimeric vaccine antigens against the avian influenza virus (AIV). Said vaccine antigens are based on viral subunits that are coupled to protein molecules that stimulate not only the cellular but also the humoral immune system. The chimeric antigens may be produced in expression systems that guarantee correct three-dimensional folding of the chimeric molecules that constitute the basis of the present invention. The vaccine compositions that contain said chimeric antigens induce a potent, early immune response both in birds and in vaccinated mammals, stimulating high haemagglutinin-inhibiting antibody titres and a potent specific cellular response against the viral antigen. The chimeric antigens, and also the resulting vaccine compositions, are applicable to the field of human and animal health as vaccines for preventive use.

Abstract: The current invention describes chimeric vaccine antigens against the virus that causes the Classic Swine Fever (CSFV). Such vaccine antigens are based on viral subunits coupled to proteins able to stimulate cellular and humoral immune system. Chimeric antigens can be produced in expression systems that guarantee a correct tertiary structure folding of the chimeric molecules, which constitute the essence of the current invention. The vaccine formulations containing such chimeric antigens induce an early and potent immune response on vaccinated pigs and confer full protection against CSFV. Moreover, the resultant vaccine formulations prevent the viral transmission from sows to their offspring. The chimeric antigens, as well as the resultant vaccine formulations, can be applied in animal health as vaccines for preventive use in swine.